GlassScriptPhysician profile
Sarah K Hanson
NPI 1982856837
$3,956.50
in general payments reported to CMS, 2019-2025
32 companies · $2,532 in 2025
The $2,532 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,424 · 2025: $2,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $462.25 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $437.26 | 2024-2025 | |
| Novo Nordisk INC | $373.87 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $322.17 | 2024-2025 | |
| Pfizer INC. | $217.60 | 2024-2025 | |
| Lundbeck LLC | $214.25 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $206.46 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $179.80 | 2024-2025 | Otezla, Repatha, Repatha |
| Viatris Specialty LLC | $164.99 | 2025 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.69 | 2025 | Caplyta |
| Mylan Specialty L.P. | $134.93 | 2024 | Yupelri |
| Abiomed | $128.26 | 2024-2025 | Impella |
| Inari Medical, INC. | $119.80 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Stryker Corporation | $88.53 | 2025 | Artix Mt, Clottriever Bold Catheter |
| Sumitomo Pharma America, INC. | $87.37 | 2025 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.16 | 2024-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $80.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $76.80 | 2024-2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.03 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $37.74 | 2025 | Symbravo, Auvelity |
| Phathom Pharmaceuticals, INC. | $37.62 | 2024-2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $37.13 | 2024 | |
| Glaxosmithkline, LLC. | $36.90 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $35.52 | 2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $32.88 | 2024-2025 | Zoryve |
| Almatica Pharma LLC | $32.19 | 2024-2025 | Loreev Xr |
| Grifols USA, LLC | $31.38 | 2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $21.46 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $20.04 | 2025 | |
| Idorsia Pharmaceuticals US INC | $17.54 | 2024 | Quviviq |
| Tonix Medicines, INC. | $14.05 | 2025 | Tonmya |
| Dynavax Technologies Corporation | $8.93 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.